Fig 1.
APL: acute promyelocytic leukemia, AI: cytarabine plus idarubicin, AD: cytarabine plus daunorubicin.
Fig 2.
Patients stratified by age group (A) and cytogenetic risk (B).
Table 1.
Baseline characteristics.
Fig 3.
Proportions of patients who received remission induction chemotherapy (A) and who achieved complete remission (CR) (B) by age group (all patients); Acute promyelocytic leukemia (APL) patients (C) and non-APL patients (D) who received remission induction chemotherapy and who achieved CR by age group.
Fig 4.
Overall survival (OS) of all patients (n = 3,011) according to age group (A) and cytogenetic risk (B).
Table 2.
Comparison of complete remission (CR) rates between patients receiving the cytarabine plus idarubicin (AI) and cytarabine plus daunorubicin (AD) treatment regimens according to age group.
Fig 5.
Overall survival (OS) comparison of cytarabine plus idarubicin (n = 1,155) and cytarabine plus daunorubicin (n = 255) in all non–acute promyelocytic leukemia patients (A), those 60 years or younger (B), and those older than 60 years (C).
Fig 6.
Overall survival (OS) comparison of cytarabine plus idarubicin and cytarabine plus daunorubicin (AD) by cytogenetic risk: Favorable risk (A), intermediate risk (B), and poor risk (C).